Antibiotic resistance in Enterobacter cloacae strains with derepressed/partly derepressed/inducible AmpC and extendedspectrum beta-lactamases in Zenica-Doboj Canton, Bosnia and Herzegovina
Abstract
Aim To investigate the prevalence of derepressed/partly derepressed/inducible and ESBL/AmpC-producing Enterobacter cloacae isolates and treatment options for infections associated with those isolates. Methods Antibiotic susceptibility was determined by disc diffusion and broth microdilution according to CLSI guidelines. Doubledisk synergy test (DDST) was performed in order to screen for ESBLs and combined disk test with phenylboronic acid to detect AmpC β-lactamases. PCR was used to detect bla ESBL /bla carb genes. Genetic relatedness of the strains was determined by pulsed-fieldgel-electrophoresis (PFGE). Results Among 14 isolates with the ESBL positive E. cloaceae producing isolates, four (28.6%), nine (64.3%) and one (7.1%) isolates were derepressed/partly derepressed and inducible AmpC producers. Eleven (out of 14) isolates were resistant to cefotaxime, ceftazidime, ceftriaxone, aminoglycosides and fluoroquinolones. All isolates were susceptible to imipenem and meropenem, 79% to cefepime. Five (out of 14; 35.7%) isolates (four derepressed and one inducible AmpC carrying E. cloaceae) were negative in phenotypic test for ESBLs, but positive for broad spectrum TEM-1 β-lactamase. One (out of four derepressed) also produced CMY-2 β-lactamase. Four (out of nine) partly derepressed isolates were positive with the DDST, but did not yield PCR products with primers targeting TEM, SHV and CTX-M beta-lactamases. Four positive partly derepressed isolates carried a bla CTX-M-1 gene, two bla OXA-1 one bla CTX-M-15, OXA-1 and one bla CTX-M-28, OXA-1 (n=1). Conclusion Microbiology laboratories must be able to detect and recognize AmpC-carrying isolates in a timely manner, especially those that are falsely susceptible in vitro to drugs that may be considered for therapy of infected patients.
Kanamori H, Yano H, Hirakata Y, Hirotani A, Arai K, Endo S, et al. Molecular characteristics of extended-spectrum beta-lactamases and qnr determinants in Enterobacter species from Japan. PLoS One. 2012. p. 37967.
2.
Bastos M, Menegucci T, Moreira R, Garcia L, Cardoso C, Tognim M. A rapid and simple method to detect ESBL in Enterobacter cloaceae based on MIC of cefepime. Revista da Sociedade Brasileria de Medicina Tropical. 2015. p. 208–11.
3.
Potron A, Poirel L, Bernabeu S, Monnet X, Richard C, Nordmann P. Nosocomial spread of ESBL-positive Enterobacter cloaceae co-expressing plasmid-mediated quinolone resistance Qnr determinants in one hospital in France. J Antimicrob Chemother. 2009. p. 653–4.
4.
Towne T, Lewis J, Herrera M, Wickers B, Jorgensen J. Detection of SHV-type extended-spectrum beta-lactamase in Enterobacter cloaceae. J Clin Microbiol. 2010. p. 298–9.
5.
Limaye A, Gautom R, Black D, Fritsche T. Rapid emergence of resistance to cefepime during treatment. Clin Infect Dis. 1997. p. 339–40.
6.
Medeiros A. Relapsing infection due to Enterobacter species: lessons of heterogeneity. Clin Infect Dis. 1997. p. 341–2.
7.
Nicolas MH, Honore N, Jarlier V, Philippon A, St C. Molecular genetic analysis of cephalosporinase production and its role in p-lactam resistance in clinical isolates of Enterobacter cloacae. Antimicrob Agents Chemother. 1987. p. 259–99.
8.
Saunders We, Tenney J, Kessler R. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 1996. p. 454–61.
9.
Pai H, Hong J, Byeon J, Kim Y, Lee H. High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8 year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother. 2004. p. 3159–61.
10.
Apfalter P, Assadian O, Daxbock F, Hirschl A, Rotter M, Makristathis A. Extended double disc synergy testing reveals a low prevalence of extendedspectrum beta-lactamases in Enterobacter spp. in Vienna. J Antimicrob Chemother. 2007. p. 854–9.
11.
Harris P, Ferguson J. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012. p. 297–305.
12.
Drew R, Ormandy E, Ball K, Lambert S, Paulus S, Williams N, et al. Antimicrobial susceptibility patterns among extended-spectrum β-lactamase-producing Enterobacteriaceae in a large Pediatric hospital in the United Kingdom. J Pediatric Infect Dis Soc. 2015. p. 147–50.
13.
Szabó D, Bonomo R, Silveira F, Pasculle A, Baxter C, Linden P, et al. SHV-type extended-spectrum betalactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. J Clin Microbiol. 2005. p. 5058–64.
14.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI; 2009.
15.
Tenover F, Emery S, Spiegel C, Bradford P, Eells S, Endimiani A, et al. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and Proteus spp. can potentially improve reporting of cephalosporins susceptibility testing results. J Clin Microbiol. 2009. p. 294–9.
16.
Mulvey M, Grant J, Plewes K, Roscoe D, Boyd D. New Delhi metallo-β-lactamase in Klebsiella pneumoniae and Escherichia coli. Canada. Emerging Infect Dis. 2011. p. 103–6.
17.
Coyle M. Manual of Antimicrobial Susceptibility testing. American Society for Microbiology; 2005.
18.
Dallenne C, Costa D, Decre A, Favier D, Arlet C, G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010. p. 490–5.
19.
Lahey Clinic. ß-Lactamase classification and amino acid sequences for TEM, SHV and OXA extendedspectrum and inhibitor resistant enzymes. 22AD.
20.
Gulamber C, Altindis M, Kalayci R, Bozdogan B, Aktepe O. Molecular characterization of nosocomial CTX-M type β-lactamase producing Enterobacteriaceae from University Hospital in Turkey. African Journal of Microbiology Research. 2012. p. 5552–7.
21.
Pasanen T, Jalava J, Horsma J, Salo E, Pakarinen M, Tarkka E, et al. An outbreak of CTX-M-15-producing Escherichia coli, Enterobacter cloacae, and Klebsiella in a children΄s hospital in Finland. Scand J Infect Dis. 2014. p. 225–30.
22.
Kaufman M. Molecular biology. Protocols and clinical applications. 1st edn. Humana Press Inc; 1998. p. 33–51.
23.
Tenover F, Arbeit R, Goering R, Mickelsen P, Murray B, Persing D, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis; criteria for bacterial strain typing. J Clin Microbiol. 1995. p. 2233–9.
24.
Izdebski R, Baraniak A, Herda M, Fiett J, Bonten M, Carmeli Y, et al. MOSAR WP2, WP3 and WP5 Study Groups. MLST reveals potentially highrisk international clones of Enterobacter cloacae. J Antimicrob Chemother. 2015. p. 48–56.
25.
Crowley B, Ratcliffe G. Extended-spectrum betalactamases in Enterobacter cloaceae: underestimated but clinically significant. J Antimicrob Chemother. 2003. p. 1316–7.
26.
Livermore D, Brown D. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother. 2001. p. 59–64.
27.
Sheng W, Badal R, Hsueh P, Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013. p. 2981–8.
28.
Thomson K. Extended-spectrum beta-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol. 2010. p. 1019–25.
29.
Jacoby G. AmpC beta-lactamases. Clin Microbiol Rev. 2009. p. 161–82.
30.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne; 2014.
31.
Stuart J, Diederen B, Naiemi A, Fluit N, Arents A, Thijsen N, et al. Leverstein-van Hall M. Method for phenotypic detection of extended-spectrum beta-lactamases in Enterobacter species in the routine clinical setting. J Clin Microbiol. 2011. p. 2711–3.
32.
Lanying C, Jinying Z, Juan L. Molecular characteristics of extended spectrum beta-lactamase and carbapenemase genes carried by carbapenem-resistant Enterobacter cloaceae in a Chinese university hospital. Turk J Med Sci. 2015. p. 1321–8.
33.
Breakpoint tables for interpretation of MICs and zone diameters. 1AD.
34.
Oteo J, Cercenado E, Vindel A, Bautista V, Fernández-Romero S, Saéz D, et al. Outbreak of multidrug-resistant CTX-M-15-producing Enterobacter cloacae in a neonatal intensive care unit. J Med Microbiol. 2013. p. 571–5.
35.
Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012. p. 268–81.
36.
Zhang R, Cai J, Zhou H, Nasu M, Chen G. Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems. J Med Microbiol. 2011. p. 1813–9.
37.
Fernández A, Pereira M, Suárez J, Poza M, Treviño M, Villalón P, et al. Emergence in Spain of a multidrug-resistant Enterobacter cloacae clinical isolate producing SFO-1 extended-spectrum beta-lactamase. J Clin Microbiol. 2011. p. 822–8.
38.
Vlieghe E, Huang T, Phe T, Bogaerts P, Berhin C, Smet D, et al. Prevalence and distribution of beta-lactamase coding genes in third-generation cephalosporin-resistant Enterobacteriaceae from bloodstream infections in Cambodia. Eur J Clin Microbiol Infect Dis. 2015. p. 41.
39.
Pagès DRA, J. Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment. Front Microbiol. 2015. p. 392.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
